CA2480683A1 - Assembled unit consisting of individually separable transdermal therapeutic systems - Google Patents
Assembled unit consisting of individually separable transdermal therapeutic systems Download PDFInfo
- Publication number
- CA2480683A1 CA2480683A1 CA002480683A CA2480683A CA2480683A1 CA 2480683 A1 CA2480683 A1 CA 2480683A1 CA 002480683 A CA002480683 A CA 002480683A CA 2480683 A CA2480683 A CA 2480683A CA 2480683 A1 CA2480683 A1 CA 2480683A1
- Authority
- CA
- Canada
- Prior art keywords
- active substance
- unit according
- transdermal
- active substances
- individually separable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
Abstract
The invention relates to an assembled unit consisting of individually separable transdermal therapeutic systems.
Description
Assembled unit consisting of individually separable, transdermal, therapeutic systems The invention relates to an assembled unit consisting of individually separable, transdermal, therapeutic systems.
Transdermal, therapeutic systems for the application of active substances to be administered transdermally are known. These are technically specified plaster systems that, while being continuously monitored over a specific period, impart a therapeutic active substance to a human or animal organism, via the skin.
In said systems, the active substance may be dispersed in a matrix or be fund in acs active substance reservoir. Both in the matrix and in the active substance reservoir, the active substance may be used in liquid, semi-solid or solid form, or as a corresponding active substance formulation.
The known transdermal, therapeutic systems contain a specific predetermined dosage of the active substance, so as to release it in a controlled manner. Administering the individual dose of the active substance, in accordance with the patient's requirements, is problematic.
According to the prior art, the individual dose is administered in various ways.
According to the teaching of DE-U-295 11 878, a strip-shaped, transdermal, therapeutic system is proposed, from which a piece may be separated, in accordance with the patient's requirements. The separation takes place in the active substance-containing region. Amounts of active substance may be lost in this way, and even small separation imprecisions may change the dosage of the active substance. It is therefore impossible to administer the dose exactly.
The publication DE 197 33 981 discloses a transdermal, therapeutic system, the active substance-containing region of which may be partially covered in order to reduce the dosage.
However, this may result in part of the active substance not being used. The contact of the active substance-containing region with the skin may also be impaired.
The publication DE 199 00 645 discloses a transdermal, therapeutic system consisting of individually separable, active substance-containing matrix portions, each of which may be applied, individually or several at once, using adhesive strips. The use of a matrix system and separated adhesive strips is, however, complicated, and does not ensure optimal contact of the adhesive substance-containing matrix portions with the skin.
The object has therefore been set of providing a transdermal, therapeutic system for the application of active substances to be administered transdermally, that is easy to use, that allows the individual dose of active substances to be administered exactly, in accordance with the patient's requirements, without losing active substance and ensuring reliable skin contact.
According to the invention, said object is achieved by providing an assembled unit consisting of at least two individually separable, transdermal, therapeutic systems, each comprising:
a) a base film that is impermeable to active substances, b) a layer that is capable of adhesion, that at least partially covers the base film, that comprises either an active substance reservoir or an active substance-containing matrix, and that has a peripheral edge region that is free of active substances, and optionally c) a detachable protective film that at least partially covers the layer that is capable of adhesion, wherein the individually separable, transdermal, therapeutic systems comprise separation facilities in their adjacent edge regions that are free of active substances.
There are preferably linear perforations for separating the individually separable, transdermal, therapeutic systems from the assembled unit according to the invention.
Cutting marks on the base film and/or the cover film, which indicates the facility for separating the individually separable systems from the unit according to the invention, are also preferred. The separation facilities are, in each case, preferably arranged such that they allow each assembled, transdermal, therapeutic system to be separated completely from the unit according to the invention.
Any active substances that may be administered transdermally, such as corticosteriods, analgesics, sedatives, tranquillisers, antibiotics, anaesthetics, antiviral agents, antimicrobial agents, fungicides, vitamins, anticonvulsants, sexual hormones, nicotine, psychopharmacological agents, coronary dilators, anti-arthritic agents, anti-asthmatic agents, antidepressants, antidiabetic agents, antihistamines, anti-inflammatory agents and/or anti-migraine agents, are suitable.
The unit according to the invention or a separated system is preferably suitable for combating pain.
The individually separable, transdermal systems comprise a base film and thereupon a layer that is capable of adhesion, that is provided with an active substance-containing matrix or an active substance reservoir, and that may optionally comprise a protective film.
The layer that is capable of adhesion may consist, at least in certain sections and preferably completely, of a matrix material that contains a component that is capable of adhesion, preferably a pressure-sensitive adhesive component, and comprises an active substance-containing region. Said active substance-containing region is surrounded by a peripheral edge region that is free of active substances.
The base film that is impermeable to active substances is preferably made of a flexible, extendable, durable material with good breathing properties. A textile-type fabric is particularly preferred. The base film may be coloured, preferably skin-coloured.
The term "impermeable to active substances" means that the base film is impermeable to active substances at least in the region in which there is an active substance-containing matrix. If the base film itself is not impermeable to active substances, a barrier layer that is impermeable to active substances should be applied between the matrix layer or the active ' CA 02480683 2004-09-27 substance reservoir and the base film. Said barner layer should preferably comprise a film-forming polymer.
The matrix material of the layer b) may be based on lipophilic or hydrophilic polymers.
S Hydrophilic polymer matrices may contain water, and are preferably gels. The matrix materials may be crosslinkable polymers, preferably synthetic resins, silicone rubbers, or rubbers such as styrene-isoprene-styrene block copolymers, silicones, polyacrylates, polyurethanes, polyvinyl ether, polyvinyl chloride, polyvinyl alcohols, polyvinylpyrrolidones, polyester, polypropylene and/or polysaccharide. Polyacrylates are particularly preferred.
The component capable of adhesion that is used for producing the layer capable of adhesion is preferably a skin-compatible polymer adhesive, particularly preferably a pressure-sensitive adhesive, such as hot melt.
In order to produce the layer that is capable of adhesion, the component that is capable of adhesion may be mixed with the above-mentioned matrix materials in known quantities, and in order to produce the active substance-containing matrix region, an active substance may be added. The active substance-containing matrix region is applied to the base film such that there is a peripheral edge region that is free of active substances. After the application, the matrix material may, if necessary, also be crosslinked. The active substance or substances that is/are found in the matrix may be in liquid, semi-solid or solid form, in the dispersed state, or be incorporated as a corresponding formulation, by adding conventional auxiliary materials as the active substance formulation.
Compounds that strengthen or facilitate the transdermal conveyance of the active substances may be used as conventional auxiliary materials. Said auxiliary materials may be mixed with the active substances or be found in a layer that is separate from the active substance-containing matrix layer.
In so far as the active substances to be applied transdermally are located in an active substance reservoir in the layer that is capable of adhesion, said reservoir is preferably embedded in the layer that is capable of adhesion. The above-mentioned polymer adhesives, which were listed as the component that is capable of adhesion, are suitable adhesives for said layer. The active substance reservoir preferably contains the active substance or the corresponding active substance formulation as a solution that is able to diffuse, unimpeded, through the membrane of the active substance reservoir. The above-mentioned polymers, which may also be used as the matrix material, are suitable membrane materials.
If, exceptionally, the active substance-containing matrix region of the layer b) does not contain a component that is capable of adhesion, the transdermal system may also be configured such that the component that is capable of adhesion, as the matrix component, is found only in the edge zone, which is free of active substances.
All of the materials that are used to construct the transdermal systems, but in particular those materials that come into contact with the skin, must be skin-compatible and physiologically safe.
The transdermal, therapeutic system according to the invention conventionally comprises a protective film, which may easily be removed prior to application, at least in the active substance-imparting region, and preferably over the entire layer that is capable of adhesion.
Said protective film is preferably made of paper, or is a physiologically safe, plastics material film that adheres easily.
The assembled unit according to the invention, consisting of individually separable, transdermal, therapeutic systems, preferably contains the same dosage of active substance for each system, as a result of which the individual, requirement-dependent application is facilitated considerably for the patient or user. This is particularly true if the active substance requirements vary, in the event of recurnng bouts of pain, for example, or if a diminishing treatment, with a decreasing dosage, is required. The application, for this purpose, of a plurality of transdermal, therapeutic systems according to the invention allows a suitable initial treatment, and the active substance dosage may easily be reduced, as appropriate, by the patient himself, during the subsequent course of the treatment, by reducing the number of systems.
The assembled unit according to the invention, consisting of individually separable, transdermal, therapeutic systems, is preferably packaged, a sterile packaging also being possible, if required.
Fig. 1 shows a plan view of a unit (1) according to the invention, consisting of four individually separable, transdermal, therapeutic systems; and Fig. 2 shows a plan view of a unit (1) according to the invention, consisting of two individually separable, transdermal, therapeutic systems.
Both in Fig. 1 and in Fig. 2, the arrows point in the direction of the separation lines (4), in this case perforations, of the respective individually separable, transdermal system of the remaining unit (1). Each individually separable system comprises an active substance-containing matrix region (3) or an active substance-containing reservoir (3a), which is surrounded by a peripheral edge region (2) that is capable of adhesion and is free of active substances. The base film and an optional protective film are not illustrated separately in Figs. 1 and 2.
Transdermal, therapeutic systems for the application of active substances to be administered transdermally are known. These are technically specified plaster systems that, while being continuously monitored over a specific period, impart a therapeutic active substance to a human or animal organism, via the skin.
In said systems, the active substance may be dispersed in a matrix or be fund in acs active substance reservoir. Both in the matrix and in the active substance reservoir, the active substance may be used in liquid, semi-solid or solid form, or as a corresponding active substance formulation.
The known transdermal, therapeutic systems contain a specific predetermined dosage of the active substance, so as to release it in a controlled manner. Administering the individual dose of the active substance, in accordance with the patient's requirements, is problematic.
According to the prior art, the individual dose is administered in various ways.
According to the teaching of DE-U-295 11 878, a strip-shaped, transdermal, therapeutic system is proposed, from which a piece may be separated, in accordance with the patient's requirements. The separation takes place in the active substance-containing region. Amounts of active substance may be lost in this way, and even small separation imprecisions may change the dosage of the active substance. It is therefore impossible to administer the dose exactly.
The publication DE 197 33 981 discloses a transdermal, therapeutic system, the active substance-containing region of which may be partially covered in order to reduce the dosage.
However, this may result in part of the active substance not being used. The contact of the active substance-containing region with the skin may also be impaired.
The publication DE 199 00 645 discloses a transdermal, therapeutic system consisting of individually separable, active substance-containing matrix portions, each of which may be applied, individually or several at once, using adhesive strips. The use of a matrix system and separated adhesive strips is, however, complicated, and does not ensure optimal contact of the adhesive substance-containing matrix portions with the skin.
The object has therefore been set of providing a transdermal, therapeutic system for the application of active substances to be administered transdermally, that is easy to use, that allows the individual dose of active substances to be administered exactly, in accordance with the patient's requirements, without losing active substance and ensuring reliable skin contact.
According to the invention, said object is achieved by providing an assembled unit consisting of at least two individually separable, transdermal, therapeutic systems, each comprising:
a) a base film that is impermeable to active substances, b) a layer that is capable of adhesion, that at least partially covers the base film, that comprises either an active substance reservoir or an active substance-containing matrix, and that has a peripheral edge region that is free of active substances, and optionally c) a detachable protective film that at least partially covers the layer that is capable of adhesion, wherein the individually separable, transdermal, therapeutic systems comprise separation facilities in their adjacent edge regions that are free of active substances.
There are preferably linear perforations for separating the individually separable, transdermal, therapeutic systems from the assembled unit according to the invention.
Cutting marks on the base film and/or the cover film, which indicates the facility for separating the individually separable systems from the unit according to the invention, are also preferred. The separation facilities are, in each case, preferably arranged such that they allow each assembled, transdermal, therapeutic system to be separated completely from the unit according to the invention.
Any active substances that may be administered transdermally, such as corticosteriods, analgesics, sedatives, tranquillisers, antibiotics, anaesthetics, antiviral agents, antimicrobial agents, fungicides, vitamins, anticonvulsants, sexual hormones, nicotine, psychopharmacological agents, coronary dilators, anti-arthritic agents, anti-asthmatic agents, antidepressants, antidiabetic agents, antihistamines, anti-inflammatory agents and/or anti-migraine agents, are suitable.
The unit according to the invention or a separated system is preferably suitable for combating pain.
The individually separable, transdermal systems comprise a base film and thereupon a layer that is capable of adhesion, that is provided with an active substance-containing matrix or an active substance reservoir, and that may optionally comprise a protective film.
The layer that is capable of adhesion may consist, at least in certain sections and preferably completely, of a matrix material that contains a component that is capable of adhesion, preferably a pressure-sensitive adhesive component, and comprises an active substance-containing region. Said active substance-containing region is surrounded by a peripheral edge region that is free of active substances.
The base film that is impermeable to active substances is preferably made of a flexible, extendable, durable material with good breathing properties. A textile-type fabric is particularly preferred. The base film may be coloured, preferably skin-coloured.
The term "impermeable to active substances" means that the base film is impermeable to active substances at least in the region in which there is an active substance-containing matrix. If the base film itself is not impermeable to active substances, a barrier layer that is impermeable to active substances should be applied between the matrix layer or the active ' CA 02480683 2004-09-27 substance reservoir and the base film. Said barner layer should preferably comprise a film-forming polymer.
The matrix material of the layer b) may be based on lipophilic or hydrophilic polymers.
S Hydrophilic polymer matrices may contain water, and are preferably gels. The matrix materials may be crosslinkable polymers, preferably synthetic resins, silicone rubbers, or rubbers such as styrene-isoprene-styrene block copolymers, silicones, polyacrylates, polyurethanes, polyvinyl ether, polyvinyl chloride, polyvinyl alcohols, polyvinylpyrrolidones, polyester, polypropylene and/or polysaccharide. Polyacrylates are particularly preferred.
The component capable of adhesion that is used for producing the layer capable of adhesion is preferably a skin-compatible polymer adhesive, particularly preferably a pressure-sensitive adhesive, such as hot melt.
In order to produce the layer that is capable of adhesion, the component that is capable of adhesion may be mixed with the above-mentioned matrix materials in known quantities, and in order to produce the active substance-containing matrix region, an active substance may be added. The active substance-containing matrix region is applied to the base film such that there is a peripheral edge region that is free of active substances. After the application, the matrix material may, if necessary, also be crosslinked. The active substance or substances that is/are found in the matrix may be in liquid, semi-solid or solid form, in the dispersed state, or be incorporated as a corresponding formulation, by adding conventional auxiliary materials as the active substance formulation.
Compounds that strengthen or facilitate the transdermal conveyance of the active substances may be used as conventional auxiliary materials. Said auxiliary materials may be mixed with the active substances or be found in a layer that is separate from the active substance-containing matrix layer.
In so far as the active substances to be applied transdermally are located in an active substance reservoir in the layer that is capable of adhesion, said reservoir is preferably embedded in the layer that is capable of adhesion. The above-mentioned polymer adhesives, which were listed as the component that is capable of adhesion, are suitable adhesives for said layer. The active substance reservoir preferably contains the active substance or the corresponding active substance formulation as a solution that is able to diffuse, unimpeded, through the membrane of the active substance reservoir. The above-mentioned polymers, which may also be used as the matrix material, are suitable membrane materials.
If, exceptionally, the active substance-containing matrix region of the layer b) does not contain a component that is capable of adhesion, the transdermal system may also be configured such that the component that is capable of adhesion, as the matrix component, is found only in the edge zone, which is free of active substances.
All of the materials that are used to construct the transdermal systems, but in particular those materials that come into contact with the skin, must be skin-compatible and physiologically safe.
The transdermal, therapeutic system according to the invention conventionally comprises a protective film, which may easily be removed prior to application, at least in the active substance-imparting region, and preferably over the entire layer that is capable of adhesion.
Said protective film is preferably made of paper, or is a physiologically safe, plastics material film that adheres easily.
The assembled unit according to the invention, consisting of individually separable, transdermal, therapeutic systems, preferably contains the same dosage of active substance for each system, as a result of which the individual, requirement-dependent application is facilitated considerably for the patient or user. This is particularly true if the active substance requirements vary, in the event of recurnng bouts of pain, for example, or if a diminishing treatment, with a decreasing dosage, is required. The application, for this purpose, of a plurality of transdermal, therapeutic systems according to the invention allows a suitable initial treatment, and the active substance dosage may easily be reduced, as appropriate, by the patient himself, during the subsequent course of the treatment, by reducing the number of systems.
The assembled unit according to the invention, consisting of individually separable, transdermal, therapeutic systems, is preferably packaged, a sterile packaging also being possible, if required.
Fig. 1 shows a plan view of a unit (1) according to the invention, consisting of four individually separable, transdermal, therapeutic systems; and Fig. 2 shows a plan view of a unit (1) according to the invention, consisting of two individually separable, transdermal, therapeutic systems.
Both in Fig. 1 and in Fig. 2, the arrows point in the direction of the separation lines (4), in this case perforations, of the respective individually separable, transdermal system of the remaining unit (1). Each individually separable system comprises an active substance-containing matrix region (3) or an active substance-containing reservoir (3a), which is surrounded by a peripheral edge region (2) that is capable of adhesion and is free of active substances. The base film and an optional protective film are not illustrated separately in Figs. 1 and 2.
Claims (8)
1. Assembled unit consisting of at least two individually separable, transdermal, therapeutic systems, each comprising:
a) a base film that is impermeable to active substances, b) a layer that is capable of adhesion, that at least partially covers the base film, that comprises either an active substance reservoir or an active substance-containing matrix, and that has a peripheral edge region that is free of active substances, and optionally c) a detachable protective film that at least partially covers the layer that is capable of adhesion, wherein the individually separable, transdermal, therapeutic systems comprise separation facilities in their adjacent edge regions that are free of active substances.
a) a base film that is impermeable to active substances, b) a layer that is capable of adhesion, that at least partially covers the base film, that comprises either an active substance reservoir or an active substance-containing matrix, and that has a peripheral edge region that is free of active substances, and optionally c) a detachable protective film that at least partially covers the layer that is capable of adhesion, wherein the individually separable, transdermal, therapeutic systems comprise separation facilities in their adjacent edge regions that are free of active substances.
2. Unit according to claim 1, characterised in that the separation facility is a perforation.
3. Unit according to claim 1, characterised in that the separation facility is indicated by a cutting mark.
4. Unit according to any one of claims 1 to 3, characterised in that the base film is made of fabric, preferably a textile-type fabric.
5. Unit according to any one of claims 1 to 4, characterised in that at least one therapeutic active substance is dispersed in a matrix or is found in the active substance reservoir.
6. Unit according to any one of claims 1 to 5, characterised in that the active substance in the active substance reservoir is in the form of a solution that is surrounded by a membrane that is permeable to active substances.
7. Unit according to any one of claims 1 to 6, characterised in that each individually separable, transdermal system contains the same dosage of active substances.
8. Unit according to any one of claims 1 to 7, characterised in that it is covered by a packaging.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10213772.2 | 2002-03-27 | ||
| DE10213772A DE10213772A1 (en) | 2002-03-27 | 2002-03-27 | Cohesive unit of singular transdermal therapeutic systems |
| PCT/EP2003/003004 WO2003079962A2 (en) | 2002-03-27 | 2003-03-22 | Assembled unit consisting of individually separable transdermal therapeutic systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2480683A1 true CA2480683A1 (en) | 2003-10-02 |
Family
ID=27816006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002480683A Abandoned CA2480683A1 (en) | 2002-03-27 | 2003-03-22 | Assembled unit consisting of individually separable transdermal therapeutic systems |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1490039A2 (en) |
| JP (1) | JP2005520844A (en) |
| AR (1) | AR039137A1 (en) |
| AU (1) | AU2003226695B2 (en) |
| CA (1) | CA2480683A1 (en) |
| DE (1) | DE10213772A1 (en) |
| PE (1) | PE20031015A1 (en) |
| PL (1) | PL370886A1 (en) |
| WO (1) | WO2003079962A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400685D0 (en) * | 2004-03-19 | 2004-03-19 | Pfizer Health Ab | Means for transdermal administration of nicotine |
| DE102004045599A1 (en) * | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System for the sequential, transdermal administration of systemically active substances |
| JP4782438B2 (en) * | 2005-02-17 | 2011-09-28 | 日東電工株式会社 | Patch preparation |
| DE202005014347U1 (en) * | 2005-09-09 | 2007-01-18 | Grünenthal GmbH | Application system for an active-ingredient release system, comprises a film-forming transparent plastic foil strip detachably connected to plaster containing an active ingredient and to controlled-release agent for the active ingredient |
| DE102006011340A1 (en) * | 2006-03-09 | 2007-09-20 | Grünenthal GmbH | Active substance-containing patches with improved handling |
| DE102006054731B4 (en) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy |
| EP2394617B1 (en) * | 2010-06-10 | 2013-12-11 | MedSkin Solutions Dr. Suwelack AG | Layer-like perforated biomatrices |
| US8936825B2 (en) | 2010-09-23 | 2015-01-20 | Monosol Rx, Llc | Method and system for forming a pharmaceutical product directly onto a packaging surface |
| CN104114161A (en) | 2011-12-12 | 2014-10-22 | Lts勒曼治疗***股份公司 | Transdermal delivery system comprising buprenorphine |
| WO2014195352A1 (en) | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
| EP3458306B1 (en) | 2016-05-18 | 2020-12-16 | Shanghai Yanfeng Jinqiao Automotive Trim Systems Co., Ltd. | Console assembly for vehicle interior |
| US11572723B2 (en) | 2019-02-27 | 2023-02-07 | Shanghai Yanfeng Jinqiao Automotive Triim Systems Co. Ltd. | Vehicle interior component |
| CN111359441B (en) * | 2020-03-25 | 2022-02-15 | 青岛科技大学 | Preparation method of chlorine-resistant reverse osmosis membrane filled with alkaline pH-responsive polymer nano container |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2449865B2 (en) * | 1974-10-17 | 1981-06-19 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Film-shaped medicinal product |
| EP0252459A1 (en) * | 1986-07-07 | 1988-01-13 | Schering Corporation | Compartmentalized transdermal delivery system |
| DE3630603A1 (en) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
| KR970008118B1 (en) * | 1987-07-09 | 1997-05-21 | 엘테에스 로오만 테라피-지스테메 게엠베하 운트 콤파니 카게 | Transdermal therapeutic system |
| DE3911617A1 (en) * | 1988-10-12 | 1990-04-19 | Klaus Brueckner | Application form for pharmaceuticals esp. for treating pain or wounds - comprises sealed packed carrier layer contg. pharmaceutical which is esp. ethereal oil |
| CA2090598A1 (en) * | 1992-03-04 | 1993-09-05 | Kirti Himatlal Valia | Titratable transdermal patch system and method for administration of therapeutic substances |
| DE4223004A1 (en) * | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Single-dose semi-solid topical dosage form for transdermal therapy |
| US5242433A (en) * | 1992-12-07 | 1993-09-07 | Creative Products Resource Associates, Ltd. | Packaging system with in-tandem applicator pads for topical drug delivery |
| DE19503336C2 (en) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Pharmaceutical form for delivering active substances to wounds, process for their preparation and their use |
| DE29511878U1 (en) * | 1995-07-22 | 1996-11-28 | Labtec Gmbh | Transdermal therapeutic systems |
| DE19900645C2 (en) * | 1999-01-11 | 2003-03-20 | Deotexis Inc | Transdermal therapeutic system |
| US6221384B1 (en) * | 1999-11-05 | 2001-04-24 | Anthony C. Pagedas | Segmented transdermal dosage unit |
| US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
-
2002
- 2002-03-27 DE DE10213772A patent/DE10213772A1/en not_active Withdrawn
-
2003
- 2003-03-22 AU AU2003226695A patent/AU2003226695B2/en not_active Ceased
- 2003-03-22 WO PCT/EP2003/003004 patent/WO2003079962A2/en active Search and Examination
- 2003-03-22 EP EP03744842A patent/EP1490039A2/en not_active Withdrawn
- 2003-03-22 PL PL03370886A patent/PL370886A1/en not_active Application Discontinuation
- 2003-03-22 JP JP2003577795A patent/JP2005520844A/en active Pending
- 2003-03-22 CA CA002480683A patent/CA2480683A1/en not_active Abandoned
- 2003-03-25 AR ARP030101040A patent/AR039137A1/en unknown
- 2003-03-25 PE PE2003000296A patent/PE20031015A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003079962A2 (en) | 2003-10-02 |
| PE20031015A1 (en) | 2004-01-17 |
| JP2005520844A (en) | 2005-07-14 |
| AU2003226695B2 (en) | 2008-10-02 |
| PL370886A1 (en) | 2005-05-30 |
| AU2003226695A1 (en) | 2003-10-08 |
| DE10213772A1 (en) | 2003-10-09 |
| AR039137A1 (en) | 2005-02-09 |
| WO2003079962A3 (en) | 2003-12-24 |
| EP1490039A2 (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU707933B2 (en) | Transdermal delivery system | |
| EP0117027B1 (en) | Drug delivery device | |
| US5091186A (en) | Biphasic transdermal drug delivery device | |
| FI91599B (en) | Patch for controlled distribution of active ingredients to the skin | |
| AU2003226695B2 (en) | Assembled unit consisting of individually separable transdermal therapeutic systems | |
| AU2004266563B2 (en) | Transdermal patch incorporating active agent migration barrier layer | |
| EP0174108B1 (en) | Transdermal delivery devices | |
| SK113790A3 (en) | Plaster as a therapeutic system, process for its manufacture and use thereof | |
| US5863941A (en) | Method and composition of a topical treatment of inner ear and labyrinth symptoms | |
| KR960005148B1 (en) | Transdermal system exhibiting graduated drug release | |
| CZ20012230A3 (en) | Transparent devices for transdermal administration of nicotine | |
| US20050118245A1 (en) | Assembled unit consisting of individually separable, transdermal, therapeutic systems | |
| US5972376A (en) | Transdermal system of tacrine/selegilin-plaster | |
| Vachhal et al. | Transdermal patches: updated review as a novel drug delivery system | |
| AU2009353789A1 (en) | Transdermal therapeutic system | |
| AU2001270537A1 (en) | Dosage of transdermal delivery systems | |
| US20070212402A1 (en) | Patch | |
| WO2001089490A1 (en) | Dosage of transdermal delivery systems | |
| KR19980701419A (en) | (s) -3-methyl-5- (1-methyl-2-pyrrolidenyl) -isoxazole or a transdermal therapeutic system for administering one of the pharmaceutically acceptable salts thereof | |
| RU2246937C2 (en) | System for transcutaneous administration of nicotine(85)18.06.2001 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |